Reactive oxygen species and mitochondrial DNA damage and repair in BCR-ABL1 cells resistant to imatinib

BioResearch Open Access

Volumn 4, Issue 1, 2015, Pages 334-342

  Blasiak, Janusz ^a   Hoser, Grazyna ^b   Bialkowska Warzecha, Jolanta ^c   Pawlowska, Elzbieta ^c   Skorski, Tomasz ^d  

^a UNIVERSITY OF LODZ   (Poland)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BCR ABL1; DNA repair; imatinib resistance; mitochondrial DNA damage repair; reactive oxygen species

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; BETA 2 MICROGLOBULIN; DOXORUBICIN; IMATINIB; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE SUBUNIT 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DRUG EXPOSURE; GENE DOSAGE; GENE MUTATION; GENOMIC INSTABILITY; LEUKEMIA CELL LINE; MITOCHONDRIAL DNA DISORDER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 85011293017     PISSN: None     EISSN: 21647860     Source Type: Journal    
DOI: 10.1089/biores.2015.0022     Document Type: Article

References (35)

1. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112:4808-4817.
2. Drake JM, Lee JK, Witte ON. Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer. Mol Cell Biol. 2014;34:1722-1732.
3. Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. Am J Hematol. 2014;89:547-576.
4. Bixby D, Talpaz M. Seeking the causes and solutions to imatinibresistance in chronic myeloid leukemia. Leukemia. 2011;25:7-22.
5. Heiblig M, Sobh M, Nicolini FE. Subcutaneous omacetaxinemepe succinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: review and perspectives. Leuk Res. 2014;38:1145-1153.
6. Leber B. CML biology for the clinician in 2011: six impossible things to believe before breakfast on the way to cure. Curr Oncol. 2011;18:e185-e190.
7. Kluza J, Jendoubi M, Ballot C, et al. Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells. PLoS One. 2011;6:e21924.
8. Koptyra M, Falinski R, Nowicki MO, et al. BCR-ABL1 kinase induces selfmutagenesis via reactive oxygen species to encode imatinib resistance. Blood. 2006;108:319-327.
9. Kazak L, Reyes A, Holt IJ. Minimizing the damage: repair pathways keep mitochondrial DNA intact. Nat Rev Mol Cell Biol. 2012;13:659-671.
10. Gottschalk S, Anderson N, Hainz C, et al. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCRABL-positive cells. Clin Cancer Res. 2004;10:6661-6668.
11. Kim JH, Chu SC, Gramlich JL, et al. Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species. Blood. 2005;105:1717-1723.
12. Klawitter J, Anderson N, Klawitter J, et al. Time-dependent effects of imatinib in human leukaemia cells: a kinetic NMR profiling study. Br J Cancer. 2009;100:923-931.
13. Kominsky DJ, Klawitter J, Brown JL, et al. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clin Cancer Res. 2009;15:3442-3450.
14. Lebrecht D, Kokkori A, Ketelsen UP, et al. Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol. 2005;207:436-444.
15. Lebrecht D, Setzer B, Rohrbach R, et al. Mitochondrial DNA and its respiratory chain products are defective in doxorubicin nephrosis. Nephrol Dial Transplant. 2004;19:329-336.
16. Slupianek A, Hoser G, Majsterek I, et al. Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis. Mol Cell Biol. 2002;22:4189-4201.
17. Karlsson M, Kurz T, Brunk UT, et al. What does the commonly used DCF test for oxidative stress really show? Biochem J. 2010;428:183-190.
18. Ballinger SW, Van Houten B, Jin GF, et al. Hydrogen peroxide causes significant mitochondrial DNA damage in human RPE cells. Exp Eye Res. 1999;68:765-772.
19. Rothfuss O, Gasser T, Patenge N. Analysis of differential DNA damage in the mitochondrial genome employing a semi-long run real-time PCR approach. Nucleic Acids Res. 2010;38:e24.
20. Hou L, Zhu ZZ, Zhang X, et al. Airborne particulate matter and mitochondrial damage: a cross-sectional study. Environ Health. 2010;9:48.
21. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101-1108.
22. Muftuoglu M, Mori MP, Souza-Pinto NC. Formation and repair of oxidative damage in the mitochondrial DNA. Miochondrion. 2014;17:164-181.
23. Barbour JA, Turner N. Mitochondrial stress signaling promotes cellular adaptations. Int J Cell Biol. 2014;2014:156020.
24. Sattler M, Verma S, Shrikhande G, et al. The BCR-ABL1 tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000;275:24273-24278.
25. Woolley JF, Corcoran A, Groeger, et al. Redox-regulated growth factor survival signaling. Antioxid Redox Signal. 2013;19:1815-1827.
26. Kalyanaraman B, Darley-Usmar V, Davies KJ, et al. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic Biol Med. 2012;52:1-6.
27. Shokolenko IN, Wilson GL, Alexeyev MF. Aging: a mitochondrial DNA perspective, critical analysis and an update. World J Exp Med. 2014;4: 46-57.
28. Tewey KM, Rowe TC, Yang L, et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 1984;226:466-468.
29. Akman SA, Doroshow JH, Burke TG, et al. DNA base modifications induced in isolated human chromatin by NADH dehydrogenase-catalyzed reduction of doxorubicin. Biochemistry. 1992;31:3500-3506.
30. Adachi K, Fujiura Y, Mayumi F, et al. A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun. 1993;195:945-951.
31. Ashley N, Poulton J. Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. Biochem Biophys Res Commun. 2009;378:450-455.
32. Alexeyev M, Shokolenko I, Wilson G, et al. The maintenance of mitochondrial DNA integrity-critical analysis and update. Cold Spring Harb Perspect Biol. 2013;5:a012641.
33. Mansouri A, Demeilliers C, Amsellem S, et al. Acute ethanol administration oxidatively damages and depletes mitochondrial DNA in mouse liver, brain, heart, and skeletal muscles: protective effects of antioxidants. J Pharmacol Exp Ther. 2001;298:737-743.
34. Hsu CW, Yin PH, Lee HC, et al. Mitochondrial DNA content as a potential marker to predict response to anthracycline in breast cancer patients. Breast J. 2010;16:264-270.
35. Palmeira CM, Serrano J, Kuehl DW, et al. Preferential oxidation of cardiac mitochondrial DNA following acute intoxication with doxorubicin. Biochim Biophys Acta. 1997;1321:101-106.